Travaglianti M, Pérez M, Sberna N, Rousseau M, Calle G, Gómez S
Servicio de Farmacia, Hospital de Pediatría Dr. Juan P. Garrahan, Buenos Aires, Argentina.
Farm Hosp. 2007 Jan-Feb;31(1):43-7. doi: 10.1016/s1130-6343(07)75710-0.
To describe the use of linezolid in vancomycin-resistant Enterococcus infections in a paediatric hospital.
Retrospective, observational study of hospitalised patients at the "Juan P. Garrahan" paediatric hospital receiving linezolid for the treatment of vancomycin-resistant Enterococcus, during the period between January 2002 and July 2004.
During 18 months, linezolid was prescribed 17 times for a total of 15 seriously ill patients. The median age was 7 years old (range: 1 month-15 years) and the median length of the treatment was 15 days, with an average hospital stay of 74 days. Infection with vancomycin-resistant Enterococcus was microbiologically documented in 11 (73.3%) patients; they all responded to treatment with linezolid with the exception of two, who died while receiving treatment. The most frequently reported adverse reactions were of a haematological nature (55.5%).
Linezolid was effective and moderately well tolerated for the treatment of vancomycin-resistant Enterococcus in children with life-threatening infections.